Aclaris Therapeutics, Inc. (ACRS) News
Follow Aclaris Therapeutics, Inc. (ACRS) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 13 public stories across 8 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
M
Aclaris Reports Third-Quarter 2026 Results, Updates on Clinical Program
Aclaris expects to initiate a Phase 2b trial of modzatinib (ATI-2138) in lichen planus in the fourth quarter.
EQUITY | Nov 05, 2026, 12:02 PM UTC
M
Aclaris Therapeutics Q3 Revenue Estimate and Results Preview
Aclaris Therapeutics is scheduled to report Q3 results on November 11. The source provides revenue and EPS estimates; report time is unspecified.
EQUITY | Nov 04, 2026, 12:01 PM UTC
M
Aclaris Reports Positive ATI-052 Phase 1b Results, Prices $50 Million Offering
EQUITY | Oct 27, 2026, 02:39 PM UTC
M
Aclaris Shares Fall 7.7% as Investors Weigh $50 Million Offering
Aclaris Therapeutics shares fell about 7.7% in premarket trading as investors weighed a discounted $50 million share offering, despite positive early-stage trial results for its experimental asthma and eczema treatment.
EQUITY | Oct 27, 2026, 12:41 PM UTC
M
Aclaris Therapeutics Prices $50 Million Stock and Warrant Offering
Aclaris Therapeutics priced a $50 million offering of common stock and pre-funded warrants.
EQUITY | Oct 27, 2026, 10:46 AM UTC
M
Aclaris Therapeutics Prices $50 Million Stock and Pre-Funded Warrant Offering
Aclaris Therapeutics announced pricing of a $50.0 million offering of common stock and pre-funded warrants.
EQUITY | Oct 27, 2026, 10:43 AM UTC
L
Aclaris ATI-052 Shows 45% Placebo-Adjusted EASI Change at Day 57
Aclaris Therapeutics said ATI-052 showed a 45% placebo-adjusted mean change in EASI score at day 57 in an atopic dermatitis trial.
EQUITY | Oct 27, 2026, 10:11 AM UTC
L
Aclaris Therapeutics to participate in Sept. 10 Cantor healthcare conference
Aclaris Therapeutics said its Chief Exec officer will present at the 2026 Cantor Global Healthcare Conference on Thursday, Sept. 10, 2026 at 2:45 PM ET.
EQUITY | Sep 03, 2026, 12:07 PM UTC
L
Aclaris Therapeutics to participate in 2026 Cantor healthcare conference
Aclaris Therapeutics (ACRS) plans to participate in the 2026 Cantor Global Healthcare Conference.
EQUITY | Sep 03, 2026, 12:00 PM UTC
L
Aclaris Therapeutics started at Buy by Canaccord Genuity
Aclaris Therapeutics (ACRS) was initiated at Buy by Canaccord Genuity.
EQUITY | Sep 01, 2026, 05:56 PM UTC
L
ACRS - Aclaris Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate and Clinical Update
ACRS - Aclaris Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate and Clinical Update
EARNINGS | Aug 06, 2026, 10:59 AM UTC
L
12 Health Care Stocks Moving In Tuesday's After-Market Session
Gainers Alzamend Neuro (NASDAQ: ALZN ) stock increased by 12.9% to $1.35 during Tuesday's after-market session. The company's market cap stands at $4.4 million. Vivos Therapeutics (NASDAQ: VVOS ) shares increased by 9.92
GEOPOLITICS | Jun 30, 2026, 09:05 PM UTC
M
SLBT Falls 11.4%
SL Science Holding Ltd shares fell sharply in pre-market trading after reporting a 35% decline in net revenue and a wider net loss for the year
EARNINGS | Jun 22, 2026, 12:03 PM UTC